Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Treg and neutrophil extracellular trap interaction contributes to the development of immunosuppression in sepsis
Yuxin Shi, Dan Wu, Yanghanzhao Wang, Yuwen Shao, Fu Zeng, Di Zhou, Hao Zhang, Changhong Miao
Yuxin Shi, Dan Wu, Yanghanzhao Wang, Yuwen Shao, Fu Zeng, Di Zhou, Hao Zhang, Changhong Miao
View: Text | PDF
Research Article Immunology Inflammation

Treg and neutrophil extracellular trap interaction contributes to the development of immunosuppression in sepsis

  • Text
  • PDF
Abstract

The excessive formation and release of neutrophil extracellular traps (NETs) in sepsis may represent a substantial mechanism contributing to multiorgan damage, which is associated with a poor prognosis. However, the precise role of NETs in mediating the transition from innate immunity to adaptive immunity during the progression of inflammation and sepsis remains incompletely elucidated. In this study, we provide evidence that, despite a reduction in the number of CD4+ T cells in the late stage of sepsis, there is a notable upregulation in the proportion of Tregs. Mechanistically, we have identified that NETs can induce metabolic reprogramming of naive CD4+ T cells through the Akt/mTOR/SREBP2 pathway, resulting in enhanced cholesterol metabolism, thereby promoting their conversion into Tregs and augmenting their functional capacity. Collectively, our findings highlight the potential therapeutic strategy of targeting intracellular cholesterol normalization for the management of immunosuppressed patients with sepsis.

Authors

Yuxin Shi, Dan Wu, Yanghanzhao Wang, Yuwen Shao, Fu Zeng, Di Zhou, Hao Zhang, Changhong Miao

×

Figure 7

Inhibition of SREBP2 prevents organ dysfunction in sepsis.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of SREBP2 prevents organ dysfunction in sepsis.
(A) Concentra...
(A) Concentration of cholesterol in sera from the sham group and CLP mice treated with or without betulin (n = 5). (B) Western blot images of SREBF2 expression in CD4+ T cells. (C) Percentage of CD4+ T cells in blood of CLP mice with or without betulin treatment on day 14 after CLP (n = 5). (D) Flow cytometric analysis of Foxp3 percentage in CD4+ T cells on day 14 after CLP (n = 5). (E) In vitro suppressive assay of Tregs isolated from CLP mice treated with betulin or PBS (n = 3). (F) The circulating levels of organ injury markers and (G) cytokines from murine plasma (n = 5). (H) Normal and septic lung sections with or without betulin treatment were subjected to H&E staining. Scale bars: 100 μm. (I) Mice pretreated with betulin or PBS induced by CLP, and were then followed for survival analysis (n = 10). The survival analysis was determined using the Kaplan-Meier method and the log-rank test. Each bar represents mean ± 95% CI. Data comparison between 2 groups was analyzed by unpaired t test. Statistical analysis for 3 or more groups was preformed using 1-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts